Sign Out
Long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (type 1) or chronic neuronopathic (type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease.
The non-neurological manifestations include ≥1 of the following conditions: anemia, after exclusion of other causes eg, iron deficiency; thrombocytopenia; bone disease, after exclusion of other causes eg, vitamin D deficiency; hepatomegaly or splenomegaly.
